Date: 2012-10-15
Type of information: Licensing agreement
Compound: ExpreS2ion\'s Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production
Company: ExpreS2ion Biotechnologies (Denmark) - the Jenner Institute (UK) University of Oxford (UK)
Therapeutic area:
Type agreement: licensing
Action mechanism: This proprietary protein expression platform, ExpreS2, is based on engineered Drosophila Schneider-2 (S2) cells to serve recombinant protein production needs in the biopharmaceutical industry as well as in academia. ExpreS2 allows quick access to proteins, excellent protein expression capability, scalability, applicability to high cell density production processes and regulatory friendliness.
Disease:
Details: Biotech company ExpreS2ion Biotechnologies has signed a research license agreement to provide the University of Oxford access to ExpreS2ion\'s Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production. The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford. The platform will be used by various research teams to address expression of complex and \"difficult-to-make\" proteins.
Financial terms:
Latest news:
